Patents Assigned to CDR-LIFE AG
  • MAGE-A4 peptide-MHC antigen binding proteins
    Patent number: 11912771
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: February 27, 2024
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner